SOX2 expression and prognostic significance in ovarian carcinoma

International Journal of Gynecological Pathology

Volumn 32, Issue 4, 2013, Pages 358-367

  Pham, Deborah L ^a   Scheble, Veit ^a   Bareiss, Petra ^a   Fischer, Anna ^a   Beschorner, Christine ^a   Adam, Annemarie ^a   Bachmann, Cornelia ^b   Neubauer, Hans ^b   Boesmueller, Hans ^d   Kanz, Lothar ^a   Wallwiener, Diethelm ^b   Fend, Falko ^a   Lengerke, Claudia ^a   Perner, Sven ^c   Fehm, Tanja ^b   Staebler, Annette ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft   (Austria)

Author keywords

Embryonic stem cell factors; Ovarian carcinoma; Prognosis; SOX2

Indexed keywords

TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX; TUMOR MARKER;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; CYSTADENOCARCINOMA; GENETICS; KAPLAN MEIER METHOD; METABOLISM; OVARY TUMOR; PATHOLOGY; PROGNOSIS;

CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; NEOPLASM GRADING; OVARIAN NEOPLASMS; PROGNOSIS; SOXB1 TRANSCRIPTION FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880211081     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31826a642b     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. van der Burg ME. Advanced ovarian cancer. Curr Treat Options Oncol 2001;2:109-18.
3. Chobanian N, Dietrich CS, III. Ovarian cancer. Surg Clin North Am 2008;88:285-99. (Pubitemid 351434416)
4. Kobel M, Kalloger SE, Baker PM, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: A transcanadian study. Am J Surg Pathol 2010;34:984-93.
5. Kobel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009;33:14-21.
6. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol 2010;34:433-43.
7. Cho KR, Shih IeM. Ovarian cancer. Annu Rev Pathol 2009;4:287-313.
8. Kuhn E, Meeker A, Wang TL, et al. Shortened telomeres in serous tubal intraepithelial carcinoma: An early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol 2010;34:829-36.
9. Mehrad M, Ning G, Chen EY, et al. A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. Adv Anat Pathol 2010;17:293-302.
10. Piek JM, Verheijen RH, van Diest PJ. Tubal and ovarian pathways to pelvic epithelial cancer: A pathological perspective. Histopathology 2009;54:494-5.
11. Park JT, Li M, Nakayama K, et al. Notch3 gene amplification in ovarian cancer. Cancer Res 2006;66:6312-8.
12. Staebler A, Karberg B, Behm J, et al. Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma. Genes Chromosomes Cancer 2006;45:905-17. (Pubitemid 44360178)
13. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009;41:1238-42.
14. Hussenet T, Dali S, Exinger J, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 2010;5:e8960:1-15.
15. Maier S, Wilbertz T, Braun M, et al. SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. Hum Pathol 2011;42:1078-88.
16. Sholl LM, Barletta JA, Yeap BY, et al. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol 2010;34:1193-8.
17. Wilbertz T, Wagner P, Petersen K, et al. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol 2011;24:944-53.
18. Fong H, Hohenstein KA, Donovan PJ. Regulation of selfrenewal and pluripotency by Sox2 in human embryonic stem cells. Stem Cells 2008;26:1931-8.
19. Avilion AA, Nicolis SK, Pevny LH, et al. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 2003;17:126-40. (Pubitemid 36062514)
20. Bani-Yaghoub M, Tremblay RG, Lei JX, et al. Role of Sox2 in the development of the mouse neocortex. Dev Biol 2006; 295:52-66. (Pubitemid 44041325)
21. de Jong J, Stoop H, Gillis AJ, et al. Differential expression of SOX17 and SOX2 in germ cells and stem cells has biological and clinical implications. J Pathol 2008;215:21-30. (Pubitemid 351619872)
22. Glinsky GV. ''Stemness'' genomics law governs clinical behavior of human cancer: Implications for decision making in disease management. J Clin Oncol 2008;26:2846-53.
23. Park JT, Chen X, Trope CG, et al. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 2010;177:1087-94.
24. Steg AD, Bevis KS, Katre AA, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 2012;18:869-81.
25. Silva IA, Bai S, McLean K, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011;71:3991-4001.
26. Zhang J, Guo X, Chang DY, et al. CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol 2012;25:456-64.
27. Ye F, Li Y, Hu Y, et al. Expression of Sox2 in human ovarian epithelial carcinoma. J Cancer Res Clin Oncol 2011;137:131-7.
28. Zhang J, Chang DY, Mercado-Uribe I, et al. Sex-determining region Y-box 2 expression predicts poor prognosis in human ovarian carcinoma. Hum Pathol 2012;25:456-64.
29. Malpica A, Deavers MT, Tornos C, et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 2007;31:1168-74. (Pubitemid 47207118)
30. Zaino RJ, Kurman RJ, Diana KL, et al. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer 1995;75:81-6.
31. Scheble VJ, Braun M, Wilbertz T, et al. ERG rearrangement in small cell prostatic and lung cancer. Histopathology 2010; 56:937-43.
32. Lengerke C, Fehm T, Kurth R, et al. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer 2011;11:42:1-10.
33. Sanada Y, Yoshida K, Konishi K, et al. Expression of gastric mucin MUC5AC and gastric transcription factor SOX2 in ampulla of vater adenocarcinoma: Comparison between expression patterns and histologic subtypes. Oncol Rep 2006;15:1157-61.
34. Santagata S, Hornick JL, Ligon KL. Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. Am J Surg Pathol 2006;30: 1613-8. (Pubitemid 44808799)
35. Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008;40:499-507. (Pubitemid 351601215)
36. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - shifting the paradigm. Hum Pathol 2011;42:918-31.
37. Chang MC, Vargas SO, Hornick JL, et al. Embryonic stem cell transcription factors and D2-40 (podoplanin) as diagnostic immunohistochemical markers in ovarian germ cell tumors. Int J Gynecol Pathol 2009;28:347-55.
38. Sanada Y, Yoshida K, Ohara M, et al. Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: Comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas 2006;32:164-70.
39. Schmitz M, Temme A, Senner V, et al. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer 2007;96:1293-301. (Pubitemid 46625072)
40. Chen Y, Shi L, Zhang L, et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008;283:17969-78.
41. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, et al. Sox2: A possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 2007;20:474-81. (Pubitemid 46482371)
42. Wu K, Jiao X, Li Z, et al. The cell-fate determination factor dachshund reprograms breast cancer stem cell function. J Biol Chem 2010;286:2132-42.
43. Chang B, Liu G, Xue F, et al. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol 2009;22:817-23.